SG11201900844UA - Amino pyrimidine ssao inhibitors - Google Patents
Amino pyrimidine ssao inhibitorsInfo
- Publication number
- SG11201900844UA SG11201900844UA SG11201900844UA SG11201900844UA SG11201900844UA SG 11201900844U A SG11201900844U A SG 11201900844UA SG 11201900844U A SG11201900844U A SG 11201900844UA SG 11201900844U A SG11201900844U A SG 11201900844UA SG 11201900844U A SG11201900844U A SG 11201900844UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indianapolis
- company
- indiana
- pct
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102100027159 Membrane primary amine oxidase Human genes 0.000 abstract 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/094833 WO2018027892A1 (en) | 2016-08-12 | 2016-08-12 | Amino pyrimidine ssao inhibitors |
| PCT/CN2017/095999 WO2018028517A1 (en) | 2016-08-12 | 2017-08-04 | Amino pyrimidine ssao inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900844UA true SG11201900844UA (en) | 2019-02-27 |
Family
ID=61161335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900844UA SG11201900844UA (en) | 2016-08-12 | 2017-08-04 | Amino pyrimidine ssao inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10287270B2 (de) |
| EP (2) | EP3497086B1 (de) |
| JP (2) | JP7035013B2 (de) |
| KR (3) | KR20240035917A (de) |
| CN (2) | CN108884056B (de) |
| AU (2) | AU2017309199B2 (de) |
| BR (1) | BR112019002275A2 (de) |
| CA (1) | CA3033687A1 (de) |
| CR (1) | CR20190124A (de) |
| DK (1) | DK3497086T3 (de) |
| ES (1) | ES2908805T3 (de) |
| HU (1) | HUE058142T2 (de) |
| IL (1) | IL264745B (de) |
| MA (1) | MA45937A (de) |
| MX (1) | MX2019001581A (de) |
| MY (1) | MY196576A (de) |
| NZ (1) | NZ750290A (de) |
| PH (1) | PH12019500296A1 (de) |
| PL (1) | PL3497086T3 (de) |
| PT (1) | PT3497086T (de) |
| SG (1) | SG11201900844UA (de) |
| WO (2) | WO2018027892A1 (de) |
| ZA (2) | ZA201901097B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018027892A1 (en) * | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) * | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
| CN109810041B (zh) * | 2017-11-21 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 |
| KR20190110740A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR20190110736A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| CN110938059A (zh) * | 2018-09-25 | 2020-03-31 | 上海轶诺药业有限公司 | 胺基脲敏感性胺氧化酶抑制剂制备及其应用 |
| WO2020063854A1 (zh) * | 2018-09-27 | 2020-04-02 | 南京明德新药研发有限公司 | 作为vap-1抑制剂的喹啉类衍生物 |
| DK3873600T5 (da) * | 2018-10-29 | 2024-03-18 | Boehringer Ingelheim Int | Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf |
| JP7425793B2 (ja) * | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
| TW202039486A (zh) | 2018-12-14 | 2020-11-01 | 南韓商柳韓洋行股份有限公司 | 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物 |
| TWI835945B (zh) | 2018-12-14 | 2024-03-21 | 南韓商柳韓洋行股份有限公司 | 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物 |
| JP2022517085A (ja) * | 2019-01-11 | 2022-03-04 | 南京薬捷安康生物科技有限公司 | ハロゲン化アリルアミン系化合物及びその適用 |
| MX2022005199A (es) | 2019-10-29 | 2022-08-04 | Eccogene Shanghai Co Ltd | Inhibidores de ssao y uso de los mismos. |
| CN113149957A (zh) * | 2020-01-23 | 2021-07-23 | 轶诺(浙江)药业有限公司 | 胺基脲敏感性胺氧化酶抑制剂制备及其应用 |
| EP4125968A4 (de) * | 2020-03-25 | 2024-04-10 | Terns, Inc. | Behandlung von atemwegserkrankungen |
| BR112022022952A2 (pt) * | 2020-05-13 | 2023-01-10 | Terns Pharmaceuticals Inc | Tratamento combinado de distúrbios hepáticos |
| MX2023002308A (es) | 2020-08-25 | 2023-07-11 | Lilly Co Eli | Polimorfos de un inhibidor de ssao. |
| CN114621243B (zh) * | 2020-12-14 | 2024-03-01 | 上海拓界生物医药科技有限公司 | 一种磺酰胺类衍生物及其用途 |
| KR20220145981A (ko) * | 2021-04-22 | 2022-11-01 | 주식회사유한양행 | 트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물 |
| AU2022387121A1 (en) * | 2021-11-11 | 2024-06-20 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| WO2023086562A1 (en) * | 2021-11-11 | 2023-05-19 | Terns Pharmaceuticals, Inc. | Treating liver disorders with an ssao inhibitor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007120528A2 (en) * | 2006-03-31 | 2007-10-25 | La Jolla Pharmaceutical Company | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
| WO2008123469A1 (ja) * | 2007-03-30 | 2008-10-16 | Japan Tobacco Inc. | ６員環アミド化合物およびその用途 |
| AU2008280784A1 (en) * | 2007-07-20 | 2009-01-29 | Merck Frosst Canada Ltd | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US8426587B2 (en) | 2007-11-21 | 2013-04-23 | Pharmaxis Ltd. | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
| JP2011136942A (ja) * | 2009-12-28 | 2011-07-14 | Kowa Co | 新規な置換ピリミジン誘導体およびこれを含有する医薬 |
| HUE028394T2 (en) | 2011-03-15 | 2016-12-28 | Astellas Pharma Inc | Guanidin Compound |
| ES2668300T3 (es) * | 2012-05-02 | 2018-05-17 | Boehringer Ingelheim International Gmbh | Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos |
| ES2606197T3 (es) * | 2012-11-16 | 2017-03-23 | Bristol-Myers Squibb Company | Moduladores pirrolidina de GPR40 |
| US8962641B2 (en) * | 2013-04-17 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
| EP2997024B1 (de) * | 2013-05-17 | 2018-03-28 | Boehringer Ingelheim International GmbH | Pyrrolidinderivate, pharmazeutische zusammensetzungen und ihre verwendungen |
| GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| WO2018027892A1 (en) * | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
-
2016
- 2016-08-12 WO PCT/CN2016/094833 patent/WO2018027892A1/en active Application Filing
-
2017
- 2017-08-04 PT PT178386470T patent/PT3497086T/pt unknown
- 2017-08-04 KR KR1020247007555A patent/KR20240035917A/ko active Search and Examination
- 2017-08-04 KR KR1020197005543A patent/KR102483876B1/ko active IP Right Grant
- 2017-08-04 BR BR112019002275A patent/BR112019002275A2/pt active Search and Examination
- 2017-08-04 EP EP17838647.0A patent/EP3497086B1/de active Active
- 2017-08-04 MY MYPI2019000694A patent/MY196576A/en unknown
- 2017-08-04 PL PL17838647T patent/PL3497086T3/pl unknown
- 2017-08-04 CA CA3033687A patent/CA3033687A1/en active Pending
- 2017-08-04 MA MA045937A patent/MA45937A/fr unknown
- 2017-08-04 CN CN201780006868.4A patent/CN108884056B/zh active Active
- 2017-08-04 JP JP2019507302A patent/JP7035013B2/ja active Active
- 2017-08-04 EP EP21206067.7A patent/EP3984996A1/de active Pending
- 2017-08-04 ES ES17838647T patent/ES2908805T3/es active Active
- 2017-08-04 NZ NZ750290A patent/NZ750290A/en unknown
- 2017-08-04 CR CR20190124A patent/CR20190124A/es unknown
- 2017-08-04 KR KR1020227045793A patent/KR102646063B1/ko active IP Right Grant
- 2017-08-04 AU AU2017309199A patent/AU2017309199B2/en active Active
- 2017-08-04 DK DK17838647.0T patent/DK3497086T3/da active
- 2017-08-04 MX MX2019001581A patent/MX2019001581A/es unknown
- 2017-08-04 SG SG11201900844UA patent/SG11201900844UA/en unknown
- 2017-08-04 HU HUE17838647A patent/HUE058142T2/hu unknown
- 2017-08-04 WO PCT/CN2017/095999 patent/WO2018028517A1/en unknown
- 2017-08-04 CN CN202111597465.6A patent/CN114380801A/zh active Pending
-
2018
- 2018-06-19 US US16/011,855 patent/US10287270B2/en active Active
-
2019
- 2019-02-10 IL IL264745A patent/IL264745B/en unknown
- 2019-02-12 PH PH12019500296A patent/PH12019500296A1/en unknown
- 2019-02-20 ZA ZA2019/01097A patent/ZA201901097B/en unknown
- 2019-03-18 US US16/356,882 patent/US10464928B2/en active Active
- 2019-09-26 US US16/584,622 patent/US10793552B2/en active Active
-
2021
- 2021-09-14 JP JP2021149451A patent/JP7372957B2/ja active Active
-
2022
- 2022-02-18 ZA ZA2022/02097A patent/ZA202202097B/en unknown
- 2022-05-06 AU AU2022203071A patent/AU2022203071B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations |